Edwards Lifesciences (EW) PT Raised to $125 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/5/2026
- Wall Street ends sharply lower as chips slide, jobs data fuels rate hike fears
- U.S. economy adds 172,000 jobs in May, topping expectations
- Citi warns global stock markets are the frothiest since 2008
- JPMorgan upgrades Tesla, sets new price target on robotaxi and Optimus potential
- Fed risks fueling a stock bubble by overlooking AI-driven inflation: BCA
- Wall Street ends sharply lower as chips slide, jobs data fuels rate hike fears
- Marvell Technology and Flex to join S&P 500; others to join S&P MidCap 400 and S&P SmallCap 600
- SpaceX signs $920 million monthly cloud deal with Google
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
Edwards Lifesciences (EW) PT Raised to $125 at Leerink Partners
April 27, 2016 12:44 PM EDTLeerink Partners analyst Danielle Antalffy reiterated an Outperform rating and boosted is price target on Edwards Lifesciences (NYSE: EW) to $125.00 (from $115.00) following continued strong results.
Antalffy commented, "Last night, EW reported yet another quarter of better than-expected sales -- now its 8th consecutive quarter of sales outperformance -- with 1Q16 adjusted sales of $695.6M (+18% y/y, +19% ex. FX), coming in ~$27M ahead of us and over $30M ahead of the Street. Again, stronger... More
Edwards Lifesciences (EW) PT Raised to $123 at Piper Jaffray
April 27, 2016 8:14 AM EDTPiper Jaffray analyst Brooks West raised his price target on Overweight-rated Edwards Lifesciences (NYSE: EW) to $123.00 (from $97.00) following another 'beat and raise' quarter.
West commented, "Edwards Lifesciences posted a strong beat-and-raise 1Q16 including revenue of $697.3M vs. consensus $664.2M (+20% y/y) and adjusted EPS of $0.71 vs. consensus... More
Edwards Lifesciences (EW) Tops Q1 EPS by 5c; Issues Solid Outlook
April 26, 2016 4:21 PM EDTEdwards Lifesciences (NYSE: EW) reported Q1 EPS of $0.71, $0.05 better than the analyst estimate of $0.66. Revenue for the quarter came in at $697.3 million versus the consensus estimate of $664.95 million.
"We are very pleased to report a strong start to 2016," said Michael A. Mussallem, chairman and CEO.... More
